Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151288 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
A Phase 1 study, sponsored by Vaxcyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,015
- Enrollment target
NCT06151288 is a Phase 1 study that has completed, run by Vaxcyte. The registered enrollment target is 1,015 participants.
The verdict
NCT06151288, a Phase 1 study, has completed, sponsored by Vaxcyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,015 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.
Interventions
- BIOLOGICAL 31 valent pneumococcal conjugate vaccine
- BIOLOGICAL 20 valent pneumococcal conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2024-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06151288
The ClinicalTrials.gov registry entry for NCT06151288 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,015 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxcyte, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 31 valent pneumococcal conjugate vaccine is the first listed.
NCT06151288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06151288 about?
NCT06151288 is a clinical study titled "Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults". The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection ...
What is the current status of trial NCT06151288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,015 participants. The study started on 2023-11-08. Estimated completion is 2024-07-17.
What interventions are being tested in trial NCT06151288?
The interventions under investigation include: 31 valent pneumococcal conjugate vaccine (BIOLOGICAL), 20 valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06151288?
This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.